Literature DB >> 17118761

Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma.

Kazuho Shimura1, Chihiro Shimazaki, Kyoko Taniguchi, Sonoko Akamatsu, Masashi Okamoto, Ryo Uchida, Ken-ichi Nomura, Tohru Inaba, Shigeo Horiike, Narisato Kanamura, Masafumi Taniwaki.   

Abstract

A 60-year-old man with multiple myeloma (MM) (IgG-kappa, stage IIIA) had been treated with minodronate at 6 mg orally as a phase 1 clinical trial for myeloma bone disease for 13 months (total dose, 4032 mg). Then he received incadronate at 10mg intravenously every 1 to 4 weeks (total dose, 350 mg). In July 2005, he complained of mild right mandibular pain, and bone scintigram showed a hot spot at the right side of the mandible. Panoramic radiograph showed osteonecrosis of the jaw (ONJ) and axial and 3-dimensional computed tomography confirmed ONJ. Oral examination showed massive gingival swelling of the right side of the mandible without exposed necrotic bone. He was given clarithromycin in addition to levofloxacin, followed by hyperbaric oxygen (HBO) therapy, which resulted in the complete disappearance of the pain. This is a first reported case of ONJ induced by incadronate. The present case suggests that early detection of ONJ by regular dental check-ups is important in the management of patients with MM who have received bisphosphonate therapy, and HBO in combination with antibiotic therapy is effective in the early stage of ONJ.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118761     DOI: 10.1532/IJH97.06110

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  16 in total

1.  Bisphosphonates: new antiangiogenic molecules in cancer treatment?

Authors:  B Vincenzi; D Santini; L Rocci; G Tonini
Journal:  Ann Oncol       Date:  2003-05       Impact factor: 32.976

2.  Intravenous bisphosphonates and osteonecrosis.

Authors:  Martin S Greenberg
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2004-09

3.  Bisphosphanates and oral cavity avascular bone necrosis.

Authors:  Cesar A Migliorati
Journal:  J Clin Oncol       Date:  2003-11-15       Impact factor: 44.544

4.  Osteonecrosis of the jaw and bisphosphonates.

Authors:  Brian G M Durie; Michael Katz; John Crowley
Journal:  N Engl J Med       Date:  2005-07-07       Impact factor: 91.245

5.  Guidelines on the diagnosis and management of multiple myeloma 2005.

Authors:  Alastair Smith; Finn Wisloff; Diana Samson
Journal:  Br J Haematol       Date:  2006-02       Impact factor: 6.998

6.  Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma.

Authors:  Naoya Ochiai; Noriko Yamada; Ryo Uchida; Shin-ichi Fuchida; Akira Okano; Mayumi Hatsuse; Masashi Okamoto; Eishi Ashihara; Chihiro Shimazaki
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

7.  Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.

Authors:  Cesar A Migliorati; Mark M Schubert; Douglas E Peterson; Luis Marcelo Seneda
Journal:  Cancer       Date:  2005-07-01       Impact factor: 6.860

8.  Hyperbaric oxygen and postradiation osteonecrosis of the mandible.

Authors:  M R McKenzie; F L Wong; J B Epstein; M Lepawsky
Journal:  Eur J Cancer B Oral Oncol       Date:  1993-07

9.  A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells.

Authors:  R Takahashi; C Shimazaki; T Inaba; A Okano; M Hatsuse; A Okamoto; H Hirai; E Ashihara; M Nakagawa
Journal:  Leuk Res       Date:  2001-01       Impact factor: 3.156

10.  American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

Authors:  James R Berenson; Bruce E Hillner; Robert A Kyle; Ken Anderson; Allan Lipton; Gary C Yee; J Sybil Biermann
Journal:  J Clin Oncol       Date:  2002-09-01       Impact factor: 44.544

View more
  9 in total

Review 1.  Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.

Authors:  Peter K Wong; Gelsomina L Borromeo; John D Wark
Journal:  Rheumatol Int       Date:  2013-05-08       Impact factor: 2.631

2.  Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy.

Authors:  Subash C Gupta; David Hevia; Sridevi Patchva; Byoungduck Park; Wonil Koh; Bharat B Aggarwal
Journal:  Antioxid Redox Signal       Date:  2012-01-16       Impact factor: 8.401

3.  Bisphosphonate-related osteonecrosis of the jaw: the Florence experience.

Authors:  Alberto Borgioli; Marco Duvina; Leila Brancato; Christian Viviani; Maria Luisa Brandi; Paolo Tonelli
Journal:  Clin Cases Miner Bone Metab       Date:  2007-01

4.  Effect of hyperbaric oxygen therapy on tooth extraction sites in rats subjected to bisphosphonate therapy-histomorphometric and immunohistochemical analysis.

Authors:  Miguel Luciano Silva; Leandro Tasso; Alan Arrieira Azambuja; Maria Antonia Figueiredo; Fernanda Gonçalves Salum; Vinicius Duval da Silva; Karen Cherubini
Journal:  Clin Oral Investig       Date:  2016-03-09       Impact factor: 3.573

5.  Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up.

Authors:  Philipp Stockmann; Eleftherios Vairaktaris; Falk Wehrhan; Martin Seiss; Stephan Schwarz; Bernd Spriewald; Friedrich-Wilhelm Neukam; Emeka Nkenke
Journal:  Support Care Cancer       Date:  2009-07-17       Impact factor: 3.603

Review 6.  Osteonecrosis of the jaws and bisphosphonates.

Authors:  David G Pendrys; Stuart L Silverman
Journal:  Curr Osteoporos Rep       Date:  2008-03       Impact factor: 5.096

7.  Effectiveness of surgery and hyperbaric oxygen for antiresorptive agent-related osteonecrosis of the jaw: A subgroup analysis by disease stage.

Authors:  Takuma Watanabe; Keita Asai; Shizuko Fukuhara; Ryuji Uozumi; Kazuhisa Bessho
Journal:  PLoS One       Date:  2021-01-04       Impact factor: 3.240

8.  Biphosphonates-related osteonecrosis of the jaw: Clinical and physiopathological considerations.

Authors:  Alberto Borgioli; Christian Viviani; Marco Duvina; Leila Brancato; Giuseppe Spinelli; Maria Luisa Brandi; Paolo Tonelli
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

9.  Clinical management of suppurative osteomyelitis, bisphosphonate-related osteonecrosis, and osteoradionecrosis: report of three cases and review of the literature.

Authors:  Eduardo Pereira Guimarães; Fernanda Rafaelly de Oliveira Pedreira; Bruno Correia Jham; Marina Lara de Carli; Alessandro Antônio Costa Pereira; João Adolfo Costa Hanemann
Journal:  Case Rep Dent       Date:  2013-10-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.